Phase I/II trial of the tolerability and preliminary efficacy of APC 100 for the treatment of hormone-refractory (castrate-resistant) prostate cancer

Trial Profile

Phase I/II trial of the tolerability and preliminary efficacy of APC 100 for the treatment of hormone-refractory (castrate-resistant) prostate cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs APC 100 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Adamis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Feb 2016 Results (n=20) published in the Investigational New Drugs
    • 15 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top